1-6 of 6
Jeremy Er
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma

Simon J. Harrison, Tamia Nguyen, Marzia Rahman, Jeremy Er, Jessica Li, Katherine Li, Nikoletta Lendvai, Jordan M. Schecter, Arnob Banerjee, Tito Roccia, Brad Foulk, Junchen Gu, Hao Zhao, Denis Smirnov, Ana Slaughter, Carolina Lonardi, Erin Lee, Loreta Marquez, Shirin Jadidi, Octavio Costa Filho, Nitin Patel, Dong Geng, Nicole M Haynes, Hannah Kelly, Stephen Lade, Sean Grimmond, Piers Blombery
Journal: Blood
Blood (2023) 142 (Supplement 1): 6939.
https://doi.org/10.1182/blood-2023-178806
Published: 2023
Journal Articles

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Noffar Bar, Joris Diels, Suzy van Sanden, João Mendes, Teresa Hernando, Patricia Cost, Jordan M. Schecter, Nikoletta Lendvai, Nitin Patel, Tadao Ishida, Jeremy Er, Simon J. Harrison, Nieves Lopez-Muñoz
Journal: Blood
Blood (2023) 142 (Supplement 1): 2141.
https://doi.org/10.1182/blood-2023-182141
Published: 2023
Journal Articles

Infectious Complications of Bispecific Antibody Therapy in Patients with Multiple Myeloma

Beatrice Z Sim, Anthony Longhitano, Jeremy Er, Simon J Harrison, Monica Slavin, Benjamin W Teh
Journal: Blood
Blood (2022) 140 (Supplement 1): 4384–4385.
https://doi.org/10.1182/blood-2022-167834
Published: 2022
Journal Articles

RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study

Carmelo Carlo-Stella, Rita Mazza, Salomon Manier, Thierry Facon, Sung-Soo Yoon, Youngil Koh, Simon J Harrison, Jeremy Er, Antonio Pinto, Francesco Volzone, Giulia Perrone, Paolo Corradini, Titouan Cazaubiel, Cyrille Hulin, Cyrille Touzeau, Philippe Moreau, Enrique M. Ocio, Carmen Maria Montes Gaisan, Rakesh Popat, Sarah Leong, Fritz Offner, Paula Rodriguez Otero, Ana Alfonso-Pierola, Ann-Marie E Bröske, Iryna Dekhtiarenko, Hans-Joachim Helms, Sara Belli, Eva Rossmann, Tanja Fauti, Jan Eckmann, Tom Moore, Meike Schneider, Wolfgang Jacob, Martin Weisser, Martin Hutchings, Caroline Hasselbalch Riley
Journal: Blood
Blood (2022) 140 (Supplement 1): 397–399.
https://doi.org/10.1182/blood-2022-157988
Published: 2022
Journal Articles

Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study

Iryna Dekhtiarenko, Iva Lelios, Jan Attig, Nassim Sleiman, Domenico Lazzaro, Emilie Schindler, Jan Eckmann, Pablo Umana, Wolfgang Jacob, Meike Schneider, Carmelo Carlo-Stella, Rita Mazza, Salomon Manier, Thierry Facon, Sung-Soo Yoon, Youngil Koh, Simon J Harrison, Jeremy Er, Antonio Pinto, Francesco Volzone, Giulia Perrone, Paolo Corradini, Titouan Cazaubiel, Cyrille Hulin, Cyrille Touzeau, Philippe Moreau, Enrique M. Ocio, Carmen Maria Montes Gaisan, Rakesh Popat, Sarah Leong, Fritz Offner, Paula Rodriguez Otero, Ana Alfonso-Pierola, Martin Hutchings, Caroline Hasselbalch Riley, Ann-Marie E Bröske
Journal: Blood
Blood (2022) 140 (Supplement 1): 10137–10139.
https://doi.org/10.1182/blood-2022-158146
Published: 2022
Journal Articles

KRd: the new KiD in the French myeloma induction class

Clinical Trials & Observations
Jeremy Er, Simon J. Harrison
Journal: Blood
Blood (2021) 138 (2): 105–106.
https://doi.org/10.1182/blood.2021011751
Published: 2021